Skip to main content
Doserly

For informational and research purposes only.

Medical DisclaimerTerms of Use

Peptide Reference Guide
Muscle Building

CJC No DAC / Ipamorelin: Modified GRF(1-29), Blend Doses and Evidence Limits

Published by Doserly
On this page

Quick Reference Card

Attribute

Identity

Research reference
This page covers the short-acting no-DAC pairing: Modified GRF(1-29), commonly sold as CJC-1295 without DAC, plus ipamorelin.

Attribute

Core distinction

Research reference
The published CJC-1295 human pharmacokinetic studies are for the DAC, albumin-binding molecule. They should not be used as dose schedules for the no-DAC blend. [1][2]

Attribute

Component roles

Research reference
Modified GRF(1-29) is the GHRH-pathway side; ipamorelin is the ghrelin-receptor/GHS-R1a side. Pairing them follows the acute GHRH plus GHRP synergy concept, but the fixed blend itself is not a proven clinical product. [4][5]

Attribute

US FDA status

Research reference
No FDA-approved fixed CJC no DAC/ipamorelin blend label was identified. FDA has listed ipamorelin acetate as a compounding safety-risk substance for outsourcing facilities, and FDA warning-letter language has treated CJC-1295 and ipamorelin products as ineligible compounded drugs in a 503A context. [6][7]

Attribute

Main dosing problem

Research reference
A blend vial amount is not a per-injection dose. A 10 mg vial often means total peptide content, commonly 5 mg plus 5 mg, while the drawn amount per administration is a separate number. [8][9]

Quick dose reference

This fixed blend has no established clinical dose. Total blend amount and per-component exposure should stay separate. Any dosing protocol should be reviewed with a qualified healthcare practitioner.

Injection under the skin (subcutaneous)

Online sourced dosing details

Reported amount
200-600 mcg total blend
Frequency
Once or twice daily
Duration
12 weeks on Peptide Schedule example
Dose adjustment
Public tiers list 200 mcg daily, 300 mcg daily, or 600 mcg twice daily
Reported range & limits
Same fixed-blend public examples span 200 mcg daily to 600 mcg twice daily total blend. No clinical minimum effective dose or safe upper limit.
Evidence and range contextReview the full source references below.
Public 1:1 blend calculator

Selected because it is an applicable fixed-blend public calculator row; component intravenous ipamorelin evidence belongs in expandable context, not the quick-dose scenario list.

Peptide Schedule lists beginner 200 mcg total once daily, moderate 300 mcg once daily, and aggressive 600 mcg twice daily for a 10 mg total blend example. PeptideDosingCalc lists 100-600 mcg total draw examples. If the vial is 1:1, per-component exposure is half the total, but other ratios change that arithmetic.

Full Dosing Reference SourcesClinical research, registered studies and online dosing sources, with their context and limitations.

These entries summarize source-reported study, label, or public protocol amounts. They are context for tracking and comparison, not personal dosing advice.

Current FDA-approved fixed blend label

No FDA-approved CJC no DAC/ipamorelin fixed-blend label and therefore no FDA-reviewed dose.

Route / population
Not applicable
Interpretation and limits
Commercial vial labels and clinic protocols are not FDA prescribing information.
Sources
[6][7]

CJC-1295 with DAC healthy-adult studies

Published human study used CJC-1295 with DAC in ascending subcutaneous dose trials; 30 or 60 mcg/kg were described as relatively well tolerated, and the estimated half-life was 5.8 to 8.1 days.

Route / population
Healthy adults, DAC form
Interpretation and limits
This is the long-acting albumin-binding molecule. It should not be borrowed for no-DAC daily-pulse dosing.
Sources
[2]

Registered CJC-1295 Phase 2 trial

Low-dose CJC-1295, high-dose CJC-1295 or placebo for 12 weeks, with 6-week follow-up.

Route / population
HIV-associated visceral obesity; terminated, no posted results
Interpretation and limits
The registry does not provide usable efficacy results for the blend and does not establish no-DAC/ipamorelin dosing.
Sources
[3]

CJC-1295 animal chemistry/pharmacology

CJC-1295 is a tetrasubstituted hGRF(1-29) analog with a maleimide albumin-binding group; in rats it produced longer plasma residence and higher GH AUC than hGRF(1-29).

Route / population
Rat and ex vivo albumin-conjugation work
Interpretation and limits
Explains why DAC lasts days. Removing the DAC changes the exposure profile.
Sources
[1]

Ipamorelin animal pharmacology

Ipamorelin released GH in rat and swine models, with swine ED50 2.3 nmol/kg, and did not significantly raise ACTH or cortisol even at very high multiples of the GH-release ED50.

Route / population
Animal pharmacology
Interpretation and limits
Supports ipamorelin selectivity language. It is not a human fixed-blend outcome trial.
Sources
[4]

Acute GHRH plus GHRP pathway synergy

GHRH plus GHRP-2 produced synergistic GH secretion under controlled conditions, with response modified by visceral fat, age and endocrine background.

Route / population
Human physiology studies
Interpretation and limits
Supports the pathway logic of pairing GHRH and GHS-R signals. It does not validate a commercial vial ratio or chronic protocol.
Sources
[5]

Peptide Schedule blend calculator

Beginner 200 mcg daily, moderate 300 mcg daily, aggressive 600 mcg twice daily; gives 10 mg total vial examples and U-100 unit math.

Route / population
Popular/community calculator
Interpretation and limits
Direct source for current online blend dose ranges. It is not a clinical trial.
Sources
[8]

PeptideDosingCalc blend calculator

Lists 100 to 600 mcg total-dose examples for a 10 mg vial, including U-100 draw amounts.

Route / population
Popular calculator
Interpretation and limits
Useful for marketplace arithmetic. If the vial is 1:1, a 200 mcg total draw corresponds to about 100 mcg of each component; different ratios change that.
Sources
[9]

Thirty distinct inspected sources were retained. No controlled human trial of the fixed CJC-1295 no-DAC/ipamorelin blend was found; public calculators provide the direct blend rows, while component and synergy literature remains context only.

Applicable product labels and human studies carry the most weight. A registry entry does not establish study results. Animal studies, public guides and forums add context; they do not establish a safe human dose limit.

Human clinical research

Registered clinical trials

Animal and laboratory research

Public dosing guides and calculators

Community reports and discussions

Why the blend numbers disagree

Three ideas often get compressed into one number: vial content, total blend dose and per-component dose. A "10 mg CJC/ipamorelin vial" often describes total vial content, not 10 mg per injection. A "200 mcg blend dose" may mean 200 mcg total peptide; in a true 1:1 blend that is approximately 100 mcg of Modified GRF(1-29) and 100 mcg of ipamorelin. The label, ratio and draw volume must all be known before the number means anything. [8][9]

What is CJC no DAC / ipamorelin?

This blend packages two short-acting GH-axis signals in one vial. The CJC no DAC side is best understood as Modified GRF(1-29), a short-acting GHRH analog. The ipamorelin side is a GHS-R1a agonist, the ghrelin-receptor pathway. The pairing is biologically plausible because GHRH-pathway and ghrelin-pathway stimulation can interact at the pituitary. [4][5]

The naming problem matters. CJC-1295 with DAC is a different exposure from no-DAC Modified GRF(1-29). The DAC form was designed to bind albumin and produce multi-day GH/IGF-1 elevation. A no-DAC blend is used in pulse-style marketplace protocols. Using the DAC trial half-life or weekly/biweekly schedules to justify no-DAC blend dosing is a category error. [1][2]

Separate GHRH and ghrelin receptor inputs to growth hormone release, with limits of evidence for the CJC no-DAC and ipamorelin blend.
Two receptor inputs into the growth-hormone axis; component research does not validate a fixed blend.

Evidence and evidence limits

The component literature is stronger than the blend literature. Ipamorelin has animal pharmacology showing selective GH release without the ACTH/cortisol pattern seen with older GHRPs. CJC-1295 has published DAC-form human pharmacokinetic studies, but those are not no-DAC blend studies. GHRH plus GHRP synergy has controlled human physiology support, but not as a commercial fixed-ratio CJC no DAC/ipamorelin vial. [2][4][5]

No reliable controlled human joint, tendon or injury-recovery trial of the fixed blend was retained. Claims about "joint repair" or "recovery stacks" should be presented as marketing or mechanism unless tied to a named controlled study. A fixed vial also makes attribution harder: changes in appetite, edema, sleep, glucose or IGF-1 cannot be cleanly assigned to one component without separate-component comparison.

Safety and regulatory context

FDA's compounding safety-risk page lists ipamorelin acetate for outsourcing-facility compounding concerns, including aggregation or peptide-related impurities, unnatural amino acids and limited safety information for certain injectable routes. FDA warning-letter language has also named CJC-1295 and ipamorelin among substances that did not meet 503A bulk-substance conditions in that inspected context. [6][7]

The practical safety concerns are the expected GH-secretagogue themes: water retention, glucose/insulin changes, injection-site issues, possible appetite changes and difficulty interpreting IGF-1 elevation when more than one GH-axis agent is used. The blend also removes dose independence. Raising ipamorelin raises Modified GRF(1-29), and lowering one lowers the other.

How to keep records useful

A useful record names the actual label ratio, total vial content, reconstitution volume, total draw amount and estimated per-component amount. It should not record "10 mg" as a dose unless 10 mg was actually administered. Doserly can keep the product label, dose math, reminders and observations together so that a vial-size label does not become a false protocol.

Frequently asked questions

Why are the 5 mg and 10 mg pages not separate guides?

They are the same concept at different vial amounts or naming conventions. Vial content affects how long a vial lasts and how concentration math works after reconstitution. It does not create a different molecule or separate evidence base.

Is CJC no DAC the same as long-acting CJC-1295?

No. The no-DAC name refers to the short-acting Modified GRF(1-29) style material sold without the drug affinity complex. The published long-acting CJC-1295 studies involve the DAC albumin-binding molecule. [1][2]

Is there a proven fixed-ratio clinical dose for the blend?

No FDA-approved fixed-blend dose and no controlled human fixed-ratio outcome trial were retained. Popular sites publish total-dose ranges such as 200 to 600 mcg, but those are marketplace protocols, not clinical consensus. [8][9]

Does the blend prove joint or tendon repair?

No. The retained evidence supports GH-axis signaling and component pharmacology, not a controlled joint or tendon repair claim for the fixed blend.

References

[1] Jette et al. Identification of CJC-1295 as a long-lasting hGRF(1-29) analog

[2] Teichman et al. Prolonged GH and IGF-1 stimulation by CJC-1295 with DAC in healthy adults

[3] ClinicalTrials.gov NCT00267527, terminated CJC-1295 Phase 2 trial in HIV-associated visceral obesity

[4] Raun et al. Ipamorelin, the first selective growth hormone secretagogue

[5] Veldhuis and Bowers. Determinants of GHRH and GHRP synergy in men

[6] FDA compounding safety-risk list including ipamorelin acetate

[7] FDA Tailor Made Compounding warning letter naming CJC-1295 and ipamorelin in 503A bulk-substance context

[8] Peptide Schedule CJC-1295 plus ipamorelin dosage calculator

[9] PeptideDosingCalc CJC-1295/ipamorelin blend calculator